The Federal Drug and Food Administration (FDA) expanded the Emergency Use Authorization (EUA) for Novavax COVID-19 Vaccine, Adjuvanted, those 12 years and older. It is a two-dose primary series, administered 3-8 weeks apart. The dosage for 12-17 years old is the same as the dosage for adults.
The SARS-CoV-2 spike protein and Matrix-M adjuvant is incorporated in the Novavax COVID-19 Vaccine, Adjuvanted, to enhance the immune response of the vaccinated individual.
Resources:
More CDPH resources and myCAvax Novavax product description will be updated shortly.
